Replies to post #190537 on Biotech Values

[willyw]

GILD's ER is thursday after close.

Abbvie just commented that they may have in the area of low teens HCV market share.

Gild may have some impressive numbers in a few days.

3 major unknowns; level of discounting, size of market share HCV, and perhaps what type of/level of guidance they will provide for Q-2.

GILD always seems to have plenty of nervous shareholders who are ready to sell. If all 3 of the factors I mention are positive at ER I think a number of investors might be inclined to hold.